What are the segmentation of Immunosuppressive drugs market?
Immunosuppressive
Drugs Market Highlights
Immunosuppressive
drugs are antirejection medicines that obstruct or prevent activity of the
immune system. The growth of the global immunosuppressive drugs market is
driven by various factors such as the rising incidence rate of autoimmune
diseases and increasing cases of organ failures with the need for organ
transplantation. However, the high costs of transplantation procedures and the
side effects of the drugs are expected to curb the growth of the global
immunosuppressive drugs market.
Immunosuppressive Drugs Market Overview and Analysis by drug type, route of administration,
application, and end user - forecast to 2030. According to MRFR analysis, the
global immunosuppressive drugs market is expected to reach USD 8658.21 million
by 2030 at 7.34% CAGR during the forecast period 2022-2030.
The
global immunosuppressive
drugs market is currently dominated by numerous
market players. The key players are involved in product launches and strategic
collaborations to strengthen their market positions. For instance, in May 2015,
Pfizer, Inc. was granted US Food and Drug Administration (FDA) approval for
Rapamune (Sirolimus) for the treatment of lymphangioleiomyomatosis (LAM).
Segmentation
The
global immunosuppressive drugs market has been segmented based on drug type,
route of administration, application, and end user.
The
market, based on drug type, has been segmented into calcineurin inhibitors,
corticosteroids, antiproliferative agents, mTOR inhibitors, IMDH inhibitors,
and others. The calcineurin inhibitors segment is likely to hold the majority
share of the global immunosuppressive drugs market owing to the high efficacy
of these drugs. This drug class is the most preferred after organ
transplantation procedures. The corticosteroids segment is expected to be the
fastest-growing as medical professionals increasingly prefer these drugs.
The
market, by route of administration, has been bifurcated into intravenous, oral,
and others. The intravenous segment is expected to be the largest, while the
oral segment is projected to be the fastest growing. Key market players for
increasingly seeking approvals for their oral immunosuppressive drugs.
The
global immunosuppressive drug market has been segmented, based on application,
into autoimmune disease, organ transplant, and others. The autoimmune disease
segment is projected to be the largest due to the increasing occurrences and
growing incidence rates of autoimmune diseases such as rheumatoid arthritis,
multiple sclerosis, and systemic lupus erythematosus. The organ transplant
segment is expected to register the highest growth rate owing to the increased
number of transplant donors and the rising number of organ transplant
procedures. The organ transplant immunosuppressive drugs segment has been further divided into kidney
transplant, liver transplant, heart transplant, and others.
The
end user segments of the market are hospitals and clinics, organ transplant
centres, and others. The hospitals and clinics segment are expected to hold the
largest market share due to the rising number of patient admissions and the
growing number of hospitals in developing economies. The organ transplant
canters segment is expected to be the fastest growing; this growth can be
attributed to the increased use of immunosuppressants post-transplant
procedures.
Regional
Analysis
The global
immunosuppressive drugs market has been divided, by region, into the Americas,
Europe, Asia-Pacific, and the Middle East & Africa. The immunosuppressive
drugs market in the Americas has further been branched into North America and
Latin America, with the North American market divided into the US and Canada.
The immunosuppressive drugs market in the Americas is projected to be the
largest during the forecast period owing to the large patient pool. The
European immunosuppressive drugs market has been classified as Western Europe
and Eastern Europe. The Western European market has further been categorized as
Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The
immunosuppressive drugs market in Asia-Pacific has been segmented into Japan,
China, India, South Korea, Australia, and the rest of Asia-Pacific. The
Asia-Pacific immunosuppressive is projected to be the fastest-growing during
the review period. The immunosuppressive drugs market in the Middle East &
Africa has been divided into the Middle East and Africa.
Immunosuppressive Drugs Market Players
The global immunosuppressive drugs market players are Accord Healthcare (US), Astellas Pharma
(Japan), F. Hoffmann-La Roche AG (Switzerland), Genzyme Co. (US),
GlaxoSmithKline PLC (UK), Bristol-Myers Squibb Company (US), Glenmark
Pharmaceuticals, Inc (India), Mylan Laboratories Inc. (US), Novartis AG
(Switzerland), Pfizer Inc. (US), Actavis, Inc. (US), and Zydus Cadila (India).
About Market
Research Future:
At Market Research
Future (MRFR), we enable our customers to unravel the complexity of various
industries through our Cooked Research Report (CRR), Half-Cooked Research
Reports (HCRR), & Consulting Services. MRFR team have supreme objective to
provide the optimum quality market research and intelligence services to our
clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New York
10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment